The mutation frequency of these 11 differentially expressed RBP genes in CRC was indeed high, and the mutation frequency of PRKDC and HELZ2 was more than 10% in the Fig. 3A. These two genes may be key therapeutic targets for CRC. Here, PRKDC is linked to colorectal carcinoma.